Healthcare / Drug Manufacturers - Specialty & GenericToronto
$3.90
+0.02 (+0.52%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $18.4M · quality 41.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
52/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$126M
P/E
48.8x
↑EV/EBITDA
6.9x
↓ROE
4.3%
↑Gross Margin
52.2%
↑Debt/Equity
0.71
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+12.2%
FCF CAGR
—
FCF margin
19.7%
FCF / Net income
9.48x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $108.3M · net income $2.2M · FCF $21.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $108.3M | $108.3M | $113.1M | $108.1M | $76.7M |
| Net Income | $2.2M | $2.2M | $-214000.00 | $1.2M | $-2.9M |
| EBITDA | $16.8M | $16.8M | $19.3M | $14.6M | $14.5M |
| EPS | 0.08 | 0.08 | -0.01 | 0.06 | -0.15 |
| Gross Margin | 52.2% | 52.2% | 52.6% | 55.5% | 49.4% |
| Operating Margin | 11.0% | 11.0% | 11.3% | 7.9% | -16.1% |
| Net Margin | 2.1% | 2.1% | -0.2% | 1.1% | -3.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.71 | 0.71 | 1.65 | 3.12 | 3.08 |
| Current Ratio | 1.12 | 1.12 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $21.3M | $21.3M | $18.4M | $-1.8M | $-8.9M |
| Returns | |||||
| ROE | 4.3% | 4.3% | -0.7% | 5.4% | -16.2% |
| Valuation | |||||
| P/E | 48.75 | 48.75 | — | 25.67 | — |
| EV/EBITDA | 6.93 | 6.93 | 4.19 | 6.05 | 7.31 |
| P/B | 1.98 | 1.98 | 1.19 | 1.41 | 3.46 |
| Growth & Yield | |||||
| Revenue Growth | -4.2% | -4.2% | 4.6% | 40.9% | — |
| EPS Growth | 900.0% | 900.0% | -116.7% | 140.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
62.9%
EPS terminal req.
$0.35
Spread vs growth
837.1%
5Y implied EPS CAGR
39.2%
EPS terminal req.
$0.42
Spread vs growth
860.8%
10Y implied EPS CAGR
23.8%
EPS terminal req.
$0.67
Spread vs growth
876.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+26.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.01 → 0.08
Residual
+26.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.